Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UNITED THERAPEUTICS Corp Director's Dealing 2024

Mar 22, 2024

30320_dirs_2024-03-22_44289d1a-f8f8-4630-b790-9c50786581bc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UNITED THERAPEUTICS Corp (UTHR)
CIK: 0001082554
Period of Report: 2024-03-21

Reporting Person: MAHON PAUL A (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-03-21 Common Stock M 6000 $117.76 Acquired 42710 Direct
2024-03-21 Common Stock S 857 $234.1121 Disposed 41853 Direct
2024-03-21 Common Stock S 238 $235.7318 Disposed 41615 Direct
2024-03-21 Common Stock S 3505 $236.7143 Disposed 38110 Direct
2024-03-21 Common Stock S 1400 $237.3601 Disposed 36710 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-03-21 Stock Options $117.76 M 6000 Disposed 2027-03-15 Common Stock (6000) Direct

Footnotes

F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F2: Includes 118 shares acquired on March 4, 2024, under the United Therapeutics Corporation Employee Stock Purchase Plan.

F3: This transaction was executed in multiple trades at prices ranging from $233.74 to $234.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $235.16 to $236.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $236.20 to $237.195. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: This transaction was executed in multiple trades at prices ranging from $237.22 to $237.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.